Is Bristol a Buy Post-Plavix
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.
Is Bristol-Myers Squibb a buy post-Plavix? David takes a closer look at the company's prospects after losing its flagship drug to patent expiration. How much will this impact the top line and does Bristol have enough up its sleeve to offset the loss and make it a bad news buy? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published David Williamsonowns shares of Johnson & Johnson and Pfizer. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter services recommendGilead Sciences, Johnson & Johnson, and Pfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.